RecruitingSchizophrenia
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Eligible age
18–65 yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Sponsor: Neurocrine Biosciences
Where it's recruiting
Arkansas
Bryant · Little Rock
California
Anaheim · Pico Rivera · San Diego · Sherman Oaks …
Florida
Hollywood · Miami Lakes
Georgia
Atlanta · Decatur · Snellville
Illinois
Chicago
Maryland
Gaithersburg
Massachusetts
Watertown
New Jersey
Marlton
New York
Staten Island · The Bronx
Texas
Austin · DeSoto · Houston
Source: ClinicalTrials.gov · NCT06963034 · last updated 2026-03-06